MetaCap

Coya Therapeutics (COYA) vs Medicinova (MNOV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova (MNOV) has outperformed Coya Therapeutics (COYA) over the past year, losing 8.4% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $67.1 million), about 1.0 times the size. Coya Therapeutics converts more of its revenue into profit, with a net margin of -267.1% versus -2928.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COYA-50.67%MNOV-8.39%
+151%+44%-63%
Nov 21, 20251 yearNov 20, 2026
COYA-37.74%MNOV-36.10%
+122%+35%-51%
Dec 26, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COYA versus MNOV key metrics
MetricCOYAMNOV
Share price$2.95$1.31
Market cap$69.20M$67.11M
1-day change-1.01%+3.15%
YTD return-49.14%0.00%
1-year return-50.67%-8.39%
5-year return—-59.32%
EPS (TTM)$-1.39$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.95M$409.66K
Revenue growth (YoY)+123.57%—
Net income (latest FY)$-21.23M$-12.00M
Operating margin-283.87%-3242.47%
Net margin-267.14%-2928.78%
52-week high$6.62$3.90
52-week low$2.72$1.22
Distance from 52-week high-55.44%-66.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+415.59%+529.77%
Average volume149.18K334.96K
Shares outstanding23.46M51.23M
Employees86
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNOV has outperformed COYA by 42.3 percentage points over the past year.
  • Coya Therapeutics is more profitable, keeping -267.1 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.

About Coya Therapeutics

COYA stock →

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

COYA vs MNOV FAQ

Which is bigger, Coya Therapeutics or Medicinova?

Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $67.11M for Medicinova (MNOV).

Which stock has performed better over the past year, COYA or MNOV?

MNOV returned -8.39% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.

Are Coya Therapeutics and Medicinova in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons